Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Accounts Payables: 2014-2025

Historic Accounts Payables for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $4.4 million.

  • Viking Therapeutics' Accounts Payables rose 1637.40% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 1637.40%. This contributed to the annual value of $9.8 million for FY2024, which is 30.63% up from last year.
  • As of Q3 2025, Viking Therapeutics' Accounts Payables stood at $4.4 million, which was down 19.68% from $5.5 million recorded in Q2 2025.
  • Over the past 5 years, Viking Therapeutics' Accounts Payables peaked at $11.1 million during Q2 2024, and registered a low of $254,000 during Q3 2024.
  • Moreover, its 3-year median value for Accounts Payables was $5.6 million (2023), whereas its average is $6.1 million.
  • In the last 5 years, Viking Therapeutics' Accounts Payables slumped by 95.55% in 2024 and then soared by 1,637.40% in 2025.
  • Viking Therapeutics' Accounts Payables (Quarterly) stood at $1.4 million in 2021, then skyrocketed by 490.65% to $8.5 million in 2022, then dropped by 11.92% to $7.5 million in 2023, then spiked by 30.63% to $9.8 million in 2024, then surged by 1,637.40% to $4.4 million in 2025.
  • Its Accounts Payables was $4.4 million in Q3 2025, compared to $5.5 million in Q2 2025 and $7.7 million in Q1 2025.